Jim Cramer's Mad Dash: ISRG STZ

NEW YORK (TheStreet) -- TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called Intuitive Surgical's (ISRG) recent earnings results a "severe disappointment" during CNBC's "Cramer's Mad Dash" segment Wednesday.

However, analysts continue to stand behind the name, Cramer said. He suggested investors listen to TheStreet's Herb Greenberg's view on the stock, which have been relatively accurate. 

Cramer added that product demand seems to be the main problem for Intuitive Surgical, evident by the 24% year-over-year decline in sales. "Stay away from ISRG," he told investors because perhaps "demand has peaked" for its medical devices. 

Turning to Constellation Brands (STZ), Cramer was much more bullish. The company beat on bottom-line estimates and provided strong fiscal year guidance. 

He said the company's 2013 acquisition of Grupo Modelo -- which includes Crown Imports LLC, the maker of Corona -- has been a real difference-maker for the company. 

Because of the deal, Cramer said shares of STZ are still cheap, despite the stock appreciating 69% in the past 12 months thanks to earnings results and guidance that continue to grow.


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)